{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:10:58Z","timestamp":1792599058319,"version":"4.5.0"},"reference-count":73,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.6373","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T11:30:36Z","timestamp":1561721436000},"page":"e196373","source":"Crossref","is-referenced-by-count":244,"title":["Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder"],"prefix":"10.1001","volume":"2","author":[{"given":"Rebecca L.","family":"Haffajee","sequence":"first","affiliation":[{"name":"Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor"},{"name":"Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewei Allison","family":"Lin","sequence":"additional","affiliation":[{"name":"Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Department of Psychiatry, University of Michigan Medical School, Ann Arbor"},{"name":"Veterans Affairs Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S. B.","family":"Bohnert","sequence":"additional","affiliation":[{"name":"Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor"},{"name":"Department of Psychiatry, University of Michigan Medical School, Ann Arbor"},{"name":"Veterans Affairs Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Goldstick","sequence":"additional","affiliation":[{"name":"Injury Prevention Center, Department of Emergency Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"5152","key":"zoi190251r1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013-2017.","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"zoi190251r3","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication\u2013assisted treatment.","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"9","key":"zoi190251r6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamapsychiatry.2016.1390","article-title":"Use of opioid agonist therapy for Medicare patients in 2013.","volume":"73","author":"Lembke","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"14","key":"zoi190251r7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013.","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"issue":"6S3","key":"zoi190251r8","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment.","volume":"54","author":"Haffajee","year":"2018","journal-title":"Am J Prev Med"},{"issue":"2","key":"zoi190251r9","doi-asserted-by":"publisher","first-page":"e187621","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States.","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi190251r10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care\u2014one small step for Congress, one giant leap for addiction treatment.","volume":"379","author":"Samet","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi190251r11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research.","volume":"28","author":"Amato","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi190251r12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2017.0001","article-title":"Opioid agonist treatment for patients with dependence on prescription opioids.","volume":"317","author":"Nielsen","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"zoi190251r13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review.","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"zoi190251r14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi190251r15","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence.","volume":"16","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi190251r16","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"zoi190251r17","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi190251r18","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","volume":"8","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"zoi190251r19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/add.12536","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study.","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"5","key":"zoi190251r20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am J Public Health"},{"issue":"12","key":"zoi190251r21","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi190251r22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"5","key":"zoi190251r23","first-page":"CD011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people.","volume":"9","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi190251r24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi190251r29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.15288\/jsad.2015.76.644","article-title":"The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis.","volume":"76","author":"Knudsen","year":"2015","journal-title":"J Stud Alcohol Drugs"},{"issue":"3","key":"zoi190251r30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/milq.2015.93.issue-3","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? the role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties.","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"key":"zoi190251r34","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.drugalcdep.2016.08.642","article-title":"Buprenorphine physician supply: relationship with state-level prescription opioid mortality.","volume":"173","author":"Knudsen","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi190251r35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder.","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"issue":"1","key":"zoi190251r36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: the influence of state policies.","volume":"48","author":"Stein","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi190251r37","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11.","volume":"34","author":"Dick","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"6S3","key":"zoi190251r38","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.amepre.2018.02.006","article-title":"Prescribing practices of rural physicians waivered to prescribe buprenorphine.","volume":"54","author":"Andrilla","year":"2018","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi190251r39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.2019.35.issue-1","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update.","volume":"35","author":"Andrilla","year":"2019","journal-title":"J Rural Health"},{"issue":"1","key":"zoi190251r40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1475-6773.12686","article-title":"Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees.","volume":"53","author":"Abraham","year":"2018","journal-title":"Health Serv Res"},{"key":"zoi190251r41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties.","volume":"93","author":"Jones","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"00","key":"zoi190251r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000523","article-title":"Disparities between US opioid overdose deaths and treatment capacity: a geospatial and descriptive analysis.","volume":"00","author":"Langabeer","year":"2019","journal-title":"J Addict Med"},{"issue":"50-51","key":"zoi190251r49","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000-2014.","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi190251r58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","article-title":"Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders.","volume":"37","author":"Komaromy","year":"2016","journal-title":"Subst Abus"},{"issue":"1","key":"zoi190251r59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis\u2014buprenorphine myths and realities.","volume":"379","author":"Wakeman","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi190251r60","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.mayocp.2018.07.001","article-title":"Telemedicine\u2019s role in addressing the opioid epidemic.","volume":"93","author":"Yang","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"zoi190251r61","doi-asserted-by":"publisher","first-page":"e0186315","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? a systematic review.","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"key":"zoi190251r63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1353\/eca.2017.0005","article-title":"Mortality and morbidity in the 21st century.","volume":"2017","author":"Case","year":"2017","journal-title":"Brookings Pap Econ Act"},{"issue":"2","key":"zoi190251r64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: no easy fix to its social and economic determinants.","volume":"108","author":"Dasgupta","year":"2018","journal-title":"Am J Public Health"},{"issue":"11","key":"zoi190251r65","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","article-title":"Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment.","volume":"316","author":"Stein","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"zoi190251r66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The untapped potential of office-based buprenorphine treatment.","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi190251r67","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2105\/AJPH.2018.304683","article-title":"Identifying unreported opioid deaths through toxicology data and vital records linkage: case study in Marion County, Indiana, 2011-2016.","volume":"108","author":"Lowder","year":"2018","journal-title":"Am J Public Health"},{"issue":"7","key":"zoi190251r68","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999-2015.","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"issue":"12","key":"zoi190251r69","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2105\/AJPH.2018.304781","article-title":"Identifying opioid overdose deaths using vital statistics data.","volume":"108","author":"Warner","year":"2018","journal-title":"Am J Public Health"},{"issue":"5","key":"zoi190251r70","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.amepre.2018.01.040","article-title":"Factors associated with county-level differences in US drug-related mortality rates.","volume":"54","author":"Monnat","year":"2018","journal-title":"Am J Prev Med"},{"issue":"6","key":"zoi190251r71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.amepre.2017.06.009","article-title":"Geographic variation in opioid and heroin involved drug poisoning mortality rates.","volume":"53","author":"Ruhm","year":"2017","journal-title":"Am J Prev Med"},{"key":"zoi190251r2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi190251r4","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHFFR2017\/NSDUHFFR2017.pdf. Accessed May 8, 2019."},{"key":"zoi190251r5","unstructured":"CharumilindS, LatkovicT, LewisR, Mendez-EscobarE; Healthcare Systems and Services Practice; McKinsey & Company. Why we need bolder action to combat the opioid epidemic. https:\/\/healthcare.mckinsey.com\/sites\/default\/files\/Why-we-need-bolder-action-to-combat-the-opioid-epidemic.pdf. Published September 2018. Accessed May 8, 2019."},{"key":"zoi190251r25","unstructured":"President\u2019s Commission on Combatting Drug Addiction and the Opioid Crisis. Final report of the President\u2019s commission on combatting drug addiction and the opioid crisis. https:\/\/www.whitehouse.gov\/sites\/whitehouse.gov\/files\/images\/Final_Report_Draft_11-15-2017.pdf. Accessed May 8, 2019."},{"key":"zoi190251r26","unstructured":"Jones A, Honermann B, Sharp A, Millett G. Where multiple forms of medication-assisted treatment are available. Health Affairs Blog. doi:10.1377\/HBLOG20180104.835958"},{"key":"zoi190251r27","unstructured":"8.12 Federal Opioid Treatment Standards. 2001:65-69. https:\/\/www.gpo.gov\/fdsys\/granule\/CFR-2002-title42-vol1\/CFR-2002-title42-vol1-sec8-12. Accessed May 8, 2019."},{"key":"zoi190251r28","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid treatment program directory. http:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx. Published 2017. Accessed September 19, 2017."},{"key":"zoi190251r31","unstructured":"106th US Congress. Drug Addiction Treatment Act of 2000; 2000:2205-2206. https:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-106publ310\/pdf\/PLAW-106publ310.pdf. Accessed May 8, 2019."},{"key":"zoi190251r32","unstructured":"114th US Congress. Comprehensive Addiction and Recovery Act of 2016. https:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-114publ198\/pdf\/PLAW-114publ198.pdf. Accessed May 8, 2019."},{"key":"zoi190251r33","unstructured":"RinaldoSG, RinaldoDW; American Society of Addiction Medicine. Advancing access to addiction medications: implications for opioid addiction treatment. http:\/\/www.asam.org\/docs\/default-source\/advocacy\/aaam_implications-for-opioid-addiction-treatment_final. Published 2013. Accessed May 8, 2019."},{"key":"zoi190251r43","unstructured":"University of Michigan Office of Research Ethics & Compliance. Operations manual: part 4. https:\/\/research-compliance.umich.edu\/operations-manual-part-4. Published 2019. Accessed April 26, 2019."},{"key":"zoi190251r44","unstructured":"Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. http:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/. Published 2019. Accessed April 25, 2019."},{"key":"zoi190251r45","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine treatment practitioner locator. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/physician-program-data\/treatment-physician-locator. Published 2017. Accessed September 19, 2017."},{"key":"zoi190251r46","unstructured":"Alkermes Inc. Vivitrol: find a treatment provider. https:\/\/www.vivitrol.com\/find-a-treatment-provider. Published 2017. Accessed May 23, 2019."},{"key":"zoi190251r47","unstructured":"US Census Bureau. Census regions and divisions of the United States. https:\/\/factfinder.census.gov\/faces\/tableservices\/jsf\/pages\/productview.xhtml?src=bkmk. Accessed May 8, 2019."},{"key":"zoi190251r48","unstructured":"Centers for Disease Control and Prevention. Multiple cause of death data. https:\/\/wonder.cdc.gov\/mcd.html. Published 2018. Accessed January 9, 2018."},{"key":"zoi190251r50","unstructured":"US Census Bureau. American Community Survey (ACS). https:\/\/www.census.gov\/programs-surveys\/acs\/news\/data-releases\/2016\/release.html#par_textimage_11. Published 2017. Accessed May 8, 2019."},{"key":"zoi190251r51","unstructured":"Robert Wood Johnson Foundation. County health rankings and roadmaps: rankings data & documentation. http:\/\/www.countyhealthrankings.org\/explore-health-rankings\/rankings-data-documentation. Published 2017. Accessed May 1, 2018."},{"key":"zoi190251r52","unstructured":"US Census Bureau. 2008-2017 Small area health insurance estimates (SAHIE) using the American Community Survey (ACS). https:\/\/www.census.gov\/data\/datasets\/time-series\/demo\/sahie\/estimates-acs.html. Published 2016. Accessed May 1, 2018."},{"key":"zoi190251r53","unstructured":"US Geological Survey National Geospatial Program. The national map. https:\/\/nationalmap.gov\/transport.html. Published 2008. Accessed May 8, 2019."},{"key":"zoi190251r54","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. NCHS urban-rural classification scheme for counties. https:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.htm. Published 2017. Accessed May 1, 2018."},{"key":"zoi190251r55","unstructured":"Centers for Disease Control and Prevention. U.S. county prescribing rates, 2016. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxcounty2016.html. Published 2019. Accessed April 4, 2019."},{"key":"zoi190251r56","unstructured":"Harvard Dataverse. MIT Election Data and Science Lab: county presidential election returns 2000-2016. Version 1. https:\/\/dataverse.harvard.edu\/dataset.xhtml?persistentId=doi:10.7910\/DVN\/VOQCHQ. Accessed April 4, 2019. doi:10.7910\/DVN\/VOQCHQ."},{"key":"zoi190251r57","unstructured":"US Census Bureau. Geography: divisions. https:\/\/www2.census.gov\/geo\/pdfs\/maps-data\/maps\/reference\/us_regdiv.pdf. Accessed May 8, 2019."},{"key":"zoi190251r62","unstructured":"Massachusetts Department of Public Health. Opioid-related overdose deaths continue to decline in Massachusetts. https:\/\/www.mass.gov\/news\/opioid-related-overdose-deaths-continue-to-decline-in-massachusetts. Published 2018. Accessed May 8, 2019."},{"key":"zoi190251r72","unstructured":"115th Congress. H.R. 6: SUPPORT for Patients and Communities Act; 2018:668. https:\/\/docs.house.gov\/billsthisweek\/20180924\/HR6-2.pdf. Accessed May 8, 2019."},{"key":"zoi190251r73","unstructured":"US Department of Health and Human Services. HHS FY 2018 budget in brief\u2014SAMHSA. https:\/\/www.hhs.gov\/about\/budget\/fy2018\/budget-in-brief\/samhsa\/index.html. Published 2018. Accessed May 8, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/6\/e196373\/17679877\/haffajee_2019_oi_190251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T11:30:46Z","timestamp":1561721446000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.6373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6373","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]}}}